Mineralys Therapeutics, Inc.首席执行官Jon Congleton日前披露减持该公司普通股。根据提交给美国证券交易委员会(SEC)的公告文件，此次股权变动已通过EDGAR电子申报系统完成备案。
投资者可通过公开渠道查阅完整申报文件。需要特别说明的是，本资讯基于SEC公开披露文件（文件索引号：0001933414-25-000078）自动生成，仅作为信息参考，不构成任何投资建议或法律意见。相关信息的准确性和完整性由原始披露方Mineralys Therapeutics, Inc.全权负责。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.